In situ CpG/αOX40/cGAMP injection generates a systemic antitumour immune response and simultaneously activates adaptive and innate immune responses, which is expected to overcome the bottleneck of ineffective treatment with PD-1/PD-L1 immune checkpoint inhibitors and provide benefits to certain cancer patients. This evidence concerns the gene CD274 and cancer.